Elevation Oncology Stock Fundamentals
| ELEV Stock | USD 2.76 0.22 7.38% |
Elevation Oncology fundamentals help investors to digest information that contributes to Elevation Oncology's financial success or failures. It also enables traders to predict the movement of Elevation Stock. The fundamental analysis module provides a way to measure Elevation Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elevation Oncology stock.
At this time, Elevation Oncology's Interest Expense is fairly stable compared to the past year. Other Operating Expenses is likely to climb to about 41.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 9.2 M in 2024. Elevation | Select Account or Indicator |
Elevation Oncology Company Shares Outstanding Analysis
Elevation Oncology's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Elevation Oncology Shares Outstanding | 54.64 M |
Most of Elevation Oncology's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elevation Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Elevation Shares Outstanding Historical Pattern
Today, most investors in Elevation Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Elevation Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Elevation Oncology shares outstanding as a starting point in their analysis.
Elevation Oncology Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Elevation Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Elevation Oncology has 54.64 M of shares currently outstending. This is 69.74% lower than that of the Biotechnology sector and 48.87% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 90.44% higher than that of the company.
Elevation Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Elevation Oncology's current stock value. Our valuation model uses many indicators to compare Elevation Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Elevation Oncology competition to find correlations between indicators driving Elevation Oncology's intrinsic value. More Info.Elevation Oncology is rated # 5 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . At this time, Elevation Oncology's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Elevation Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Elevation Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elevation Oncology's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Elevation Oncology could also be used in its relative valuation, which is a method of valuing Elevation Oncology by comparing valuation metrics of similar companies.Elevation Oncology is currently under evaluation in shares outstanding category among its peers.
Elevation Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Elevation Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Elevation Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Elevation Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 77.56 M | ||||
| Shares Outstanding | 54.64 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 91.28 % | ||||
| Number Of Shares Shorted | 5.31 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (40.3 M) | ||||
| Net Income | (45.7 M) | ||||
| Cash And Equivalents | 122.54 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 30.14 M | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 1.47 X | ||||
| Cash Flow From Operations | (56.18 M) | ||||
| Short Ratio | 6.60 X | ||||
| Earnings Per Share | (0.85) X | ||||
| Target Price | 8.17 | ||||
| Number Of Employees | 29 | ||||
| Beta | 1.53 | ||||
| Market Capitalization | 150.8 M | ||||
| Total Asset | 89.09 M | ||||
| Retained Earnings | (195.97 M) | ||||
| Working Capital | 83.82 M | ||||
| Net Asset | 89.09 M |
About Elevation Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elevation Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elevation Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elevation Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 39 K | 27.2 K |
Pair Trading with Elevation Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elevation Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elevation Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Elevation Stock
Moving against Elevation Stock
| 0.6 | HCM | HUTCHMED DRC | PairCorr |
| 0.56 | RZLT | Rezolute Fiscal Year End 12th of September 2024 | PairCorr |
| 0.56 | ALVO | Alvotech | PairCorr |
| 0.51 | LPCN | Lipocine | PairCorr |
| 0.47 | LLY | Eli Lilly | PairCorr |
The ability to find closely correlated positions to Elevation Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elevation Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elevation Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elevation Oncology to buy it.
The correlation of Elevation Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elevation Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elevation Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elevation Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.